We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.

Original languageEnglish (US)
Article number102437
JournalMultiple Sclerosis and Related Disorders
StatePublished - Oct 2020


  • Azetidines/therapeutic use
  • Benzyl Compounds/therapeutic use
  • Betacoronavirus/drug effects
  • Coronavirus Infections/complications
  • Enzyme Inhibitors/therapeutic use
  • Fingolimod Hydrochloride/therapeutic use
  • Humans
  • Multiple Sclerosis/drug therapy
  • Pandemics
  • Pneumonia, Viral/complications
  • Respiratory Distress Syndrome, Adult/drug therapy
  • rhoA GTP-Binding Protein/antagonists & inhibitors

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients'. Together they form a unique fingerprint.

Cite this